Clinical stage biotechnology company working on therapies for complement mediated diseases, with operations in the United States and China. Its lead candidate KP104 is a bifunctional biologic that inhibits both the classical and alternative complement pathways, in development for conditions including paroxysmal nocturnal haemoglobinuria and complement mediated kidney disease, alongside a wider complement focused discovery pipeline.
No comments available.
Leave your rating & comment